000 01588 a2200409 4500
005 20250514064453.0
264 0 _c20030508
008 200305s 0 0 eng d
022 _a0091-6749
024 7 _a10.1067/mai.2003.1382
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMenzies-Gow, Andrew
245 0 0 _aAnti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
_h[electronic resource]
260 _bThe Journal of allergy and clinical immunology
_cApr 2003
300 _a714-9 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAntigens, CD34
_xanalysis
650 0 4 _aAsthma
_xblood
650 0 4 _aBone Marrow Cells
_xdrug effects
650 0 4 _aBronchi
_xdrug effects
650 0 4 _aDouble-Blind Method
650 0 4 _aEosinophils
_xdrug effects
650 0 4 _aHematopoietic Stem Cells
_xdrug effects
650 0 4 _aHumans
650 0 4 _aInterleukin-5
_xanalysis
700 1 _aFlood-Page, Patrick
700 1 _aSehmi, Roma
700 1 _aBurman, John
700 1 _aHamid, Qutayba
700 1 _aRobinson, Douglas S
700 1 _aKay, A Barry
700 1 _aDenburg, Judah
773 0 _tThe Journal of allergy and clinical immunology
_gvol. 111
_gno. 4
_gp. 714-9
856 4 0 _uhttps://doi.org/10.1067/mai.2003.1382
_zAvailable from publisher's website
999 _c12495844
_d12495844